Streetwise Reports' Article Archives — Current Month (5)
Medical Co.'s TULSA-PRO Installed Base Growth and CAPTAIN Trial Data Could Accelerate Adoption in 2026" (03/09/2026)
Leede Financial maintained its rating on Profound Medical Corp. (PROF:NASDAQ; PRN:TSX), citing strong TULSA-PRO capital sales, expanding installed base, and upcoming CAPTAIN trial results at EAU meeting as key catalysts.
Cannabis Producer Moves to the TSX as Analyst Flags Major Expansion Potential (03/09/2026)
Cannara Biotech Inc. (LOVE:TSX; LOVFF:OTCQX; BCB0:FSE) began trading on the Toronto Stock Exchange on March 2 after graduating from the TSX Venture Exchange. Atrium Research initiated coverage with a BUY rating and CA$3.00 target, citing best-in-class EBITDA margins of 29%.
Target Raised on CA Pharma Co. as EBITDA Margins Sustain Upward Trajectory (03/06/2026)
Leede Financial maintains its current rating on CareRx and raised its target price, following FQ425 results showing continued sequential improvement in EBITDA, margins, and operating cash flow.
Record Profits, a Vape Market Landgrab, and a CA$250M Facility Bought for CA$27M (03/05/2026)
Atrium Research initiated coverage on Cannara Biotech Inc. (LOVE:TSX; LOVFF:OTCQX; BCB0:FSE), citing the company's dominant position in Quebec's new vape category, best-in-class EBITDA margins of 29%, and a capital-efficient expansion path at its Valleyfield facility that could unlock 100,000 kg of annual production capacity by FY30.
Biotech With Groundbreaking Diabetes Treatment Secures CA$7.1M Breakthrough Financing (03/05/2026)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTC; PSH:XETRA) successfully secured financing transactions totaling CA$7.1 million, significantly bolstering the company's financial stability. Find out how one analyst rates the stock.
More Archives
2025Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2024Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
